Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)

NCT03725059 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

1240

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer

Interventions

BIOLOGICAL: Pembrolizumab (K)
DRUG: Placebo (P)
DRUG: Paclitaxel (X)
DRUG: Doxorubicin (A)
DRUG: Epirubicin (E)
DRUG: Cyclophosphamide (C)
DRUG: Endocrine therapy
RADIATION: Radiation therapy
PROCEDURE: Surgery

Sponsor

Merck Sharp & Dohme LLC